USFDA approval granted for generic Bromfenac Ophthalmic Solution

Alembic's successful USFDA approval for Bromfenac Ophthalmic Solution is a positive development for both the company and patients.

53
USFDA Drug product Approval
USFDA Approval

Last Updated on July 12, 2024 by The Health Master

USFDA approval

Alembic Pharmaceuticals, a leading generic drug manufacturer in India, has secured a significant USFDA approval from the US Food and Drug Administration (USFDA).

The company recently announced final USFDA approval for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.07%.

This USFDA approval marks a major step forward in providing patients with a cost-effective option for managing postoperative inflammation and ocular pain following cataract surgery.

Understanding Bromfenac Ophthalmic Solution

  • Therapeutic Category: Bromfenac Ophthalmic Solution, 0.07%, falls under the category of nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Medical Use: This medication is specifically indicated for treating postoperative inflammation and reducing ocular pain experienced by patients who have undergone cataract surgery.

Key Points About the USFDA Approval

Generic Equivalent:

The approved ANDA is deemed therapeutically equivalent to the reference listed drug (RLD), Prolensa Ophthalmic Solution, 0.07%, manufactured by Bausch & Lomb.

This signifies that Bromfenac Ophthalmic Solution offers the same safety and efficacy profile as the brand-name drug.

Market Potential:

Bromfenac Ophthalmic Solution addresses a sizable market.

According to IQVIA data, the market size for this type of medication is estimated at USD 168 million for the twelve months ending March 2024.

This USFDA approval positions Alembic to tap into this lucrative market segment.

Alembic’s ANDA Expertise:

This recent USFDA approval further strengthens Alembic’s position as a frontrunner in the ANDA space.

With this addition, the company boasts a cumulative total of 207 ANDA approvals from the USFDA, including 180 final USFDA approvals and 27 tentative USFDA approvals.

This demonstrates Alembic’s proven track record of developing and receiving USFDA approvals for high-quality generic medications.

Looking Ahead

Alembic’s successful USFDA approval for Bromfenac Ophthalmic Solution is a positive development for both the company and patients.

It signifies Alembic’s commitment to providing accessible and affordable treatment options for patients in the United States.

With its proven efficacy and anticipated market potential, Bromfenac Ophthalmic Solution is poised to become a valuable addition to the post-cataract surgery care regimen.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news